Tech Company Financing Transactions
Laigo Bio Funding Round
Laigo Bio closed a $19.5 million Seed funding round on 3/23/2026. Backers included Kurma Partners, Angelini Ventures and Cancer Research Institute.
Transaction Overview
Company Name
Announced On
3/23/2026
Transaction Type
Venture Equity
Amount
$19,500,000
Round
Seed
Investors
Proceeds Purpose
Laigo intends to use the funds to accelerate the development of its Surface Removal Targeting Chimeras (SureTACs) oncology programs towards the clinic, as well as advance its three candidate programs for selected autoimmune and immunology indications, and graft rejection.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Yalelaan 62, Life Sciences Incubator Rm 2.04, Utrecht Scienc
Utrecht, 3584 CM
The Netherlands
Utrecht, 3584 CM
The Netherlands
Phone
Undisclosed
Website
Email Address
Overview
Laigo Bio is at the forefront of a revolutionary era in biotechnology - one that offers new hope for eradicating disease-causing targets through protein degradation. Even targets that have long eluded traditional therapeutic approaches are now within reach. At Laigo Bio, we have devised a novel technology (SureTACs) that facilitates the precise removal of proteins located on any cell surface.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthew Baker
Browse more venture capital transactions:
Prev: 3/23/2026: Mayson venture capital transaction
Next: 3/23/2026: QCraft venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs